Login to Your Account



OCD Trial Flop Disappointment for Transcept Pharmaceuticals

By Catherine Shaffer
Staff Writer

Wednesday, December 26, 2012
Top-line results from a Phase II trial of TO-2061, for obsessive compulsive disorder, were a let-down for Transcept Pharmaceuticals Inc., of Point Richmond, Calif. The data showed that TO-2061 failed to meet its primary efficacy endpoint of improving OCD symptoms compared to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription